(Q40318387)

English

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy

scientific article published on 8 February 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

vector-borne disease

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

Christopher H. Contag

object named as

Christopher H Contag

4

0 references

author name string

Stephen H Thorne

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Betty Y Y Tam

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

David H Kirn

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Calvin J Kuo

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

8 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

938-946

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

VEGF-targeted therapy: therapeutic potential and recent advances

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Tumour vascular targeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Disrupting tumour blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Altering the tropism of lentiviral vectors through pseudotyping

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Design and development of polymers for gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Adeno-associated virus vectors: potential applications for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Versatility of gene therapy vectors through viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Transcriptionally targeted adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Regulatable gene expression systems for gene therapy applications: progress and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Getting oncolytic virus therapies off the ground

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Cellular targets for transformation by the adenovirus E1A proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Combination therapy with conditionally replicating adenovirus and replication defective adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Bevacizumab in combination chemotherapy for colorectal and other cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.12.010

7 January 2021

Identifiers

10.1016/J.YMTHE.2005.12.010

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40318387&oldid=1895046072"